最新刊期

      YANG Jing, ZHANG Xinyu, ZHENG Lei, GUAN Yuyao, CHANG Wenlai, LIN Zhongkun, ZHANG Yahui, FU Zheng

      摘要：ObjectiveTo investigate the effect of gene polymorphism on adverse reactions（ADR） of constipation induced by opioids.Methods We first conducted evidence-based medical data analysis on the research of genes related to opioid adverse reactions, and selected target genes; Then 50 patients with severe constipation and 50 patients with cancer pain without adverse drug reactions after taking opioid drugs were included as the test group and the control group for 1:1 matched case study; The target gene was detected by polymerase chain reaction （PCR） or in situ hybridization and correlation analysis was performed. Finally, combined with the clinical data of patients such as age, sex, dosage and duration of medication, we used multivariate logistic regression analysis to explore the relevant predictive factors affecting the occurrence of opioid constipation adverse reactions.ResultsCYP2D6, CYP3A5*3, ABCB1 and OPRM1 were selected as target genes for detection; SNPStats genetic model analysis showed that CYP3A5*3 （058rs776746, A>G）, OPRM1 （047rs1799971, A>G） polymorphisms were associated with opioid induced constipation, among which CYP3A5*3 （058rs776746） GG, AG, OPRM1 （047rs1799971） AA, AG were risk factors for opioid induced constipation. At the same time, combined with clinical data, logistic regression analysis showed that the duration of drug use, CYP3A5*3 and OPRM1 gene polymorphisms could all be used as predictors of constipation in patients using opioids.ConclusionCYP3A5*3 （058rs776746, A>G）, OPRM1 （047rs1799971, A>G） polymorphisms are associated with opioid induced constipation, which is expected to become a clinical predictor of adverse drug reactions of opioids, and more attention should be paid to the occurrence of severe constipation in patients who have been taking opioids for a long time.  
      关键词：Pharmacogenomics;Adverse drug reactions;constipation;individualized medication   
      487
      |
      334
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 40671372 false
      更新时间：2025-09-25
      摘要：To provide prevention and control strategies of occupational exposure risks for cytotoxic drugs in medical institutions, improve the awareness of protection among medical staff, and reduce potential occupational exposure risks, the “Guidelines for Occupational Exposure Risk Protection of Cytotoxic Drugs in Medical Institutions” was developed. Based on the World Health Organization (WHO) guidelines development manual, we collected the exposure risk issues in seven stages after the cytotoxic drugs entered the hospital, such as transportation, receipt, storage, unpacking, dispensing, used of finished products, and waste disposal. The Delphi method was used to construct identify clinical issues, and evidence-based research methods were used to develop relevant evidences. Quality evaluation was conducted using the GRADE method, and consensus was reached on the recommendation opinions and evidence levels through expert consensus method. By combining engineering controls, administrative controls and personal protective equipment at different levels, a graded control approach was established. A total of 37 clinical issues were identified, resulting 36 recommendations. This guideline provides reference and supplementation for the formulation of cytotoxic drugs prevention and control measures in medical institutions.  
      关键词：occupational exposure;Risk prevention;Guideline.   
      730
      |
      209
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 40699749 false
      更新时间：2025-09-25

      XU Feifei, BIAN Yuan, HAN Yong, YAN Junfeng, TONG Rongsheng

      摘要：At present, there is a lack of unified and standardized management for the rational use of national key monitoring drugs. According to the relevant requirements of the state, in order to make the national key monitored drugs more reasonable use and standardized management in medical institutions at all levels, the Clinical pharmacy Branch of the Chinese Medical Association, the Pharmaceutical Epidemiology Special Committee of the Chinese Pharmaceutical Association and the Pharmaceutical Epidemiology Special Committee of the Sichuan Pharmaceutical Association organized experts to fully discuss, based on the relevant literature published at home and abroad in recent years and combined with the management practice of many medical institutions across the country on the national key monitored drugs, Form this management standard. This standard mainly provides relevant opinions and suggestions on the basic principles of rational use of key monitored drugs and the regulatory measures for key monitored drugs, especially on how to strengthen the pharmaceutical management and use management of key monitored drugs.  
      关键词：Reasonable medication;Management norms;Clinical pharmacist   
      732
      |
      534
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 40842729 false
      更新时间：2025-09-25
    0